JP2012515165A5 - - Google Patents

Download PDF

Info

Publication number
JP2012515165A5
JP2012515165A5 JP2011545498A JP2011545498A JP2012515165A5 JP 2012515165 A5 JP2012515165 A5 JP 2012515165A5 JP 2011545498 A JP2011545498 A JP 2011545498A JP 2011545498 A JP2011545498 A JP 2011545498A JP 2012515165 A5 JP2012515165 A5 JP 2012515165A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
composition according
mammalian
ranges
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011545498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515165A (ja
JP5981141B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/020673 external-priority patent/WO2010081112A1/en
Publication of JP2012515165A publication Critical patent/JP2012515165A/ja
Publication of JP2012515165A5 publication Critical patent/JP2012515165A5/ja
Application granted granted Critical
Publication of JP5981141B2 publication Critical patent/JP5981141B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011545498A 2009-01-12 2010-01-11 多臓器不全症候群（ｍｏｄｓ）の予防および／または処置のためのインターロイキン−２２の使用 Expired - Fee Related JP5981141B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14413409P 2009-01-12 2009-01-12
US61/144,134 2009-01-12
PCT/US2010/020673 WO2010081112A1 (en) 2009-01-12 2010-01-11 Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22

Publications (3)

Publication Number Publication Date
JP2012515165A JP2012515165A (ja) 2012-07-05
JP2012515165A5 true JP2012515165A5 (https=) 2013-02-28
JP5981141B2 JP5981141B2 (ja) 2016-08-31

Family

ID=42316862

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011545498A Expired - Fee Related JP5981141B2 (ja) 2009-01-12 2010-01-11 多臓器不全症候群（ｍｏｄｓ）の予防および／または処置のためのインターロイキン−２２の使用

Country Status (7)

Country Link
US (1) US8956605B2 (https=)
EP (1) EP2385841B1 (https=)
JP (1) JP5981141B2 (https=)
CN (1) CN102348463B (https=)
AU (1) AU2010203446B2 (https=)
CA (1) CA2748392C (https=)
WO (1) WO2010081112A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
EP3385277A1 (en) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Il-22 polypeptides and il-22 fc fusion proteins and methods of use
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
EP4106794A4 (en) 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd METHOD FOR TREATING TRANSPLANT AND HOST DISEASE
CN112007146A (zh) * 2020-09-03 2020-12-01 上海市儿童医院 Il-22在治疗和/或预防脓毒症诱发的肝脏损伤的药物中的用途
US20240033232A1 (en) * 2021-03-10 2024-02-01 Wen Tan New use of (R)-B2-agonists in treatment of sepsis and acute respiratory distress syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2329274A1 (en) 1998-05-29 1999-12-02 Steven M. Ruben Interleukin-21
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
US7226591B2 (en) * 2000-05-22 2007-06-05 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
CN100515491C (zh) * 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
CA2652924A1 (en) * 2006-06-19 2007-12-27 Wyeth Methods of modulating il-22 and il-17
WO2008085229A2 (en) * 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
CN101168049A (zh) * 2007-10-23 2008-04-30 中国人民解放军军事医学科学院基础医学研究所 白介素-22在制备治疗肝病药物中的应用及其制备方法

Similar Documents

Publication Publication Date Title
JP2012515165A5 (https=)
Li et al. Role of interleukin-17 in acute pancreatitis
Parat The biology of caveolae: achievements and perspectives
Gao et al. The potential role of IL-33/ST2 signaling in fibrotic diseases
JP2017081972A5 (https=)
NO20082434L (no) Materialer og fremgangsmater for behandling av kroniske fibrotiske sykdommer
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
JP2007262090A5 (https=)
JP2011511805A5 (https=)
JP2013503110A5 (https=)
WO2011084808A3 (en) Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
JP2008513467A5 (https=)
WO2010107177A3 (ko) 캠펜을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물
WO2011156453A3 (en) Therapeutic peptides
JP2017141225A5 (https=)
JP2015513535A5 (https=)
NZ601592A (en) Recombinant elastase proteins and methods of manufacturing and use thereof
DK2089032T3 (da) Farmaceutisk præparat der har antipsykotisk, antidepressiv eller antiepileptisk aktivitet med reducerede bivirkninger
WO2006100679A3 (en) Recombinant antibodies against human type ii transglutaminase and uses thereof
JP2020502134A5 (https=)
JP2014532758A5 (https=)
WO2007121545A8 (en) S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
Hansdottir et al. Smoking disrupts vitamin D metabolism in the lungs
Xiao et al. Anti‐interleukin‐5‐neutralizing antibody attenuates caradiac injury and cadiac dysfunction by aggravating the inflammatory response in doxorubicin‐treated mice
JP2013507383A5 (https=)